DE202022100001U1 - A system for formulating 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H-1, 3,4-thiadiazine-2-yl)thiazolidin-4-ones - Google Patents

Abstract

System for Formulating 2-(4-Bromophenyl)-3-(5-(5-(2-Nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H-1,3 ,4-thiadiazine-2-yl)thiazolidin-4-one, the system comprising:
a first compound formulating unit for preparing the first compound (E)-3-(2-nitrophenyl)-1-phenylprop-2-en-1-one by stirring 0.1 mole each of acetophenone and o-nitrobenzaldehyde in 25 ml of ethanol , after which an aqueous KOH solution of 15 ml is added into the stirred mixture, after which the mixture is refluxed in a water bath for 6 hours;
a second compound formulating unit for preparing the second compound 1-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)ethanone using a mixture of 0.01 moles of chalcone derivatives in acetic acid of 10 ml and 0.01 M hydrazine hydrate in absolute ethanol of 25 ml is refluxed for 5 hours in a water bath;
a third compound formulating unit for preparing the third compound N-(4-bromobenzylidene)-5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H-1, 3,4-thiadiazine-2-amine, using a mixture of 0.1 mole of 1-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)ethanone, 0.1 mole p -bromobenzaldehyde and 0.1 mole of thiosemicarbozide in dimethyl carbonate in the presence of the catalyst NH4OAc is refluxed on the water bath for 5 hours, resulting in the formation of the thiazole Schiff's base; and
a final compound formulation unit for preparing the final compound 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H-1 ,3,4-thiadiazine-2-yl)thiazolidin-4-one using a mixture of 0.01 mole of N-(4-bromobenzylidene)-5-(5-(2-nitrophenyl)-3-phenyl-4,5- dihydro-1H-pyrazol-1-yl)-2H-1,3,4-thiadiazine-2-amine and 0.01 M thioglycolic acid containing a trace of anhydrous ZnCl ₂ in dimethylformamide (DMF) for 6 hours at reflux .

Description

The present disclosure relates to a system for formulating 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl )-2H-1,3,4-thiadiazine-2-yl)thiazolidin-4-one

BACKGROUND OF THE INVENTION

The general formula part of various natural and synthetic compounds is the C ₃ H ₃ NS formula. The thiazole nucleus is able to form free carbene particles that interact with the various transition metals that can be used in various fields of application. The complexes and the innate thiazole molecules are useful as biocatalysts and have various necessary biological applications.

Various diseases can be treated by the use of thiazole, with diseases such as cancer, HIV, malaria and hypertension being treated by thiazole and used in anti-cancer, anti-microbial, anti-inflammatory and anti-ulcer drugs. The thiazole molecule can undergo various chemical interactions to be used in various medical and pharmaceutical applications, which is why it is of great use in the synthesis of new drugs for treatment.

In view of the foregoing, it is apparent that there is a need for a system for formulating 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H -pyrazol-1-yl)-2H-1,3,4-thiadiazine-2-yl)thiazolidin-4-one.

SUMMARY OF THE INVENTION

The present disclosure relates to a system or formulation of 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1 H -pyrazole-1 -yl)-2H-1,3,4-thiadiazine-2-yl)thiazolidin-4-one. In this disclosure, a first compound is first made, then a second compound is made with that compound, and then a third, and thereafter a final compound is made which is 2-(4-bromophenyl)-3-(5-(5-(2 -nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H-1,3,4-thiadiazine-2-yl)thiazolidin-4-one. The final compound C27H21BrN6O3S2 is prepared using 0.01 mole of N-(4-bromobenzylidene)-5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)- 2H-1,3,4-thiadiazine-2-amine and thioglycolic acid containing traces of anhydrous ZnCl2 in dimethylformamide (DMMF), which are then refluxed for 6 hours. The resulting mixture is poured onto crushed ice and stirred vigorously. After mixing, it solidifies within 15 minutes. The solidified substance is then filtered off and washed with cold water. The pure sample is obtained after recrystallization from ethanol.

The present disclosure aims to provide a system for formulating 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1- yl)-2H-1,3,4-thiadiazine-2-yl)thiazolidin-4-one. The system comprises: a first compound formulation unit for preparing the first compound (E)-3-(2-nitrophenyl)-1-phenylprop-2-en-1-one, wherein 0.1 mole of each of acetophenone and o-nitrobenzaldehyde in 25 ml of ethanol are stirred, after which an aqueous KOH solution of 15 ml is added to the stirred mixture, after which the mixture is refluxed on a water bath for 6 hours; a second compound formulating unit for preparing the second compound 1-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)ethanone using a mixture of 0.01 moles of chalcone derivatives in acetic acid of 10 ml and 0.01 M hydrazine hydrate in absolute ethanol of 25 ml are refluxed for 5 hours on the water bath; a third compound formulating unit for preparing the third compound N-(4-bromobenzylidene)-5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H-1, 3,4-thiadiazine-2-amine using a mixture of 0.1 mole of 1-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)ethanone, 0.1 moles of p-bromobenzaldehyde and 0.1 mole of thiosemicarbozide in dimethyl carbonate in the presence of the catalyst NH4OAc for 5 hours in a water bath at reflux, resulting in the formation of the thiazole Schiff's base; and a final compound formulation unit for preparing the final compound 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H- 1,3,4-thiadiazin-2-yl)thiazolidin-4-one wherein a mixture of 0.01 mole of N-(4-bromobenzylidene)-5-(5-(2-nitrophenyl)-3-phenyl-4,5 -dihydro-1H-pyrazol-1-yl)-2H-1,3,4-thiadiazine-2-amine and 0.01 M thioglycolic acid containing a trace of anhydrous ZnCl2 in dimethylformamide (DMF) at reflux for 6 hours is heated.

An object of the present disclosure is to provide a system for formulating 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1 -yl)-2H-1,3,4-thiadiazine-2-yl)thiazolidin-4-one.

Another object of the present disclosure is to provide a formulation having anti-cancer, anti-microbial, anti-inflammatory and anti-ulcer effects for drugs offers; and
another object of the present disclosure is to provide a formulation for the effective treatment of various diseases such as cancer, HIV, malaria and hypertension.

In order to further clarify the advantages and features of the present disclosure, a more detailed description of the invention is provided by reference to specific embodiments that are illustrated in the accompanying figures. It is understood that these figures represent only typical embodiments of the invention and therefore should not be considered as limiting the scope of the invention. The invention will be described and illustrated with additional specificity and detail with the accompanying figures.

character list

• 1 zeigt ein Blockdiagramm eines Systems zur Formulierung von 2-(4-Bromphenyl)-3-(5-(5-(2-Nitrophenyl)-3-phenyl-4, 5-dihydro-1H-pyrazol-1-yl)-2H-1,3,4-thiadiazin-2-yl)thiazolidin-4-on in Übereinstimmung mit einer Ausführungsform der vorliegenden Offenbarung;
• 2 zeigt die Struktur der hergestellten Endverbindung gemäß einer Ausführungsform der vorliegenden Offenbarung; und
• 3 zeigt die Strukturdarstellung für die Formulierung von 2-(4-Bromphenyl)-3-(5-(5-(2-Nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-l-yl)-2H-1,3,4-thiadiazin-2-yl)thiazolidin-4-on in Übereinstimmung mit einer Ausführungsform der vorliegenden Offenbarung.

These and other features, aspects, and advantages of the present disclosure will be better understood when the following detailed description is read with reference to the accompanying figures, in which like characters represent like parts throughout the figures, wherein:

• 1 Figure 12 shows a block diagram of a system for formulating 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H -1,3,4-thiadiazine-2-yl)thiazolidin-4-one in accordance with an embodiment of the present disclosure;
• 2 FIG. 12 shows the structure of the final connection made according to an embodiment of the present disclosure; FIG. and
• 3 Figure 1 shows the structural representation for the formulation of 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H- 1,3,4-thiadiazine-2-yl)thiazolidin-4-one in accordance with an embodiment of the present disclosure.

Those skilled in the art will understand that the elements in the figures are presented for simplicity and are not necessarily drawn to scale. For example, the flow charts illustrate the method of key steps to enhance understanding of aspects of the present disclosure. Furthermore, one or more components of the device may be represented in the figures by conventional symbols and the figures show only the specific details relevant to an understanding of the embodiments of the present disclosure, in order not to obscure the figures with details overload that are readily apparent to those skilled in the art familiar with the present specification.

DETAILED DESCRIPTION:

For the purposes of promoting an understanding of the invention, reference will now be made to the embodiment illustrated in the figures and specific language will be used to describe the same. It should be understood, however, that no limitation on the scope of the invention is intended, and such alterations and further modifications to the illustrated system and such further applications of the principles of the invention set forth therein are contemplated as would occur to those skilled in the art invention would normally come to mind.

Those skilled in the art will understand that the foregoing general description and the following detailed description are exemplary and explanatory of the invention and are not intended to be limiting.

When this specification refers to "an aspect," "another aspect," or the like, it means that a particular feature, structure, or characteristic described in connection with the embodiment is present in at least one embodiment included in the present disclosure. Therefore, the phrases "in one embodiment," "in another embodiment," and similar phrases throughout this specification may or may not all refer to the same embodiment.

The terms "comprises," "including," or other variations thereof are intended to cover non-exclusive inclusion such that a method or method that includes a list of steps includes not only those steps, but may also include other steps that are not expressly stated or pertaining to any such process or method. Likewise, any device or subsystem or element or structure or component preceded by "comprises...a" does not, without further limitation, exclude the existence of other devices or other subsystem or other element or other structure or other component or additional device or additional subsystems or additional elements or additional structures or additional components.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one skilled in the art to which this invention pertains. The system, methods and examples given here are for illustrative purposes only and are not intended to be limiting.

Embodiments of the present disclosure are described in detail below with reference to the attached figures.

1 Figure 12 shows a block diagram of a system for formulating 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H -1,3,4-thiadiazine-2-yl)thiazolidin-4-one in accordance with an embodiment of the present disclosure. The system 100 includes a first compound formulation unit 102 for preparing the first compound (E)-3-(2-nitrophenyl)-1-phenylprop-2-en-1-one, using 0.1 mole of both the acetophenone and the o-nitrobenzaldehyde in 25 ml of ethanol are stirred, after which an aqueous KOH solution of 15 ml is added into the stirred mixture, after which the mixture is refluxed in a water bath for 6 hours.

In one embodiment, a second compound formulation unit 104 is used to prepare the second compound 1-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)ethanone using a mixture of 0.01 moles of chalcone derivatives in 10 ml of acetic acid and 0.01 moles of hydrazine hydrate in 25 ml of absolute ethanol for 5 hours in a water bath under reflux.

In one embodiment, a third compound formulation unit 106 is used to produce the third compound N-(4-bromobenzylidene)-5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl) -2H-1,3,4-thiadiazine-2-amine is used, using a mixture of 0.1 mole of 1-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl )ethanone, 0.1 mol p-bromobenzaldehyde, and 0.1 mol thiosemicarcarbozide in dimethyl carbonate in the presence of the catalyst NH ₄ OAc is refluxed on the water bath for 5 hours, leading to the formation of the thiazole Schiff's base.

In one embodiment, a final compound formulation unit 108 for preparing the final compound 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl) -2H-1,3,4-thiadiazine-2-yl)thiazolidin-4-one using a mixture of 0.01 mole of N-(4-bromobenzylidene)-5-(5-(2-nitrophenyl)-3-phenyl- 4,5-dihydro-1H-pyrazol-1-yl)-2H-1,3,4-thiadiazine-2-amine and 0.01 mole thioglycolic acid containing a trace of anhydrous ZnCl ₂ in dimethylformamide (DMF) for 6 hours is heated under reflux.

In one embodiment, the reaction to produce the first compound is monitored by thin layer chromatography (TLC) with hexane-chloroform and the reaction mixture is poured into crushed ice which is then acidified with dilute HCl to give a chalcone precipitate which is then filtered and washed with ethanol is crystallized.

In one embodiment, the first compound (E)-3-(2-nitrophenyl)-1-phenylprop-2-en-1-one has a melting point of 149-150°C and a molecular weight of 253.25, the yield of the compound being 84 % amounts to.

In one embodiment, after the completion of the reaction of the second compound, the mixture is concentrated by distillation under reduced pressure and, after cooling, a solid is obtained, which is then dried and purified by recrystallization from methanol, the yield being 81%, the melting point 153-154° C and the molecular weight is 309.32.

In one embodiment, the reaction to produce the third compound is monitored by thin layer chromatography (TLC) with hexane-chloroform and the reaction mixture is poured into the crushed ice whereupon the compound precipitates as a solid which is then filtered and crystallized from ethanol to give the yield of the third compound is 79%, the melting point is 131-132°C and the molecular weight is 547.43.

In one embodiment, the mixture, which has been refluxed for 6 hours to produce the final compound, is then poured into crushed ice and then stirred vigorously, after which it solidifies within 15 minutes, filtered off and washed with cold water, after which the pure Sample is obtained by recrystallization from ethanol, the yield being 77%, the melting point being 135-136°C and the molecular weight being 621.53.

2 Figure 12 shows the structure of the final connection made according to an embodiment of the present disclosure. To prepare the final compound, a mixture of 0.01 mole of the third compound and 0.01 mole of thioglycolic acid containing traces of anhydrous ZnCl ₂ in dimethylformamide (DMF) is refluxed for six hours and then poured into crushed ice and then stirred vigorously, whereupon it solidifies within fifteen minutes, filtered off and washed with cold water, after which the pure sample is obtained by recrystallization from ethanol.

The chemical formula for the final compound 2-(4-Bromophenyl)-3-(5-(5-(2-Nitrophenyl)-3 -phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H -1 ,3,4-thiadiazi n-2-yl)thiazolidin-4-one is C ₂₇ H ₂₁ BrN ₆ O ₃ S ₂ . The yield is 77%, the melting point is 135-136°C and the molecular weight is 621.53.

3 Figure 1 shows the structural representation for the formulation of 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H- 1,3,4-thiadiazine-2-yl)thiazolidin-4-one in accordance with an embodiment of the present disclosure. First, a first compound (E)-3-(2-nitrophenyl)-1-phenylprop-2-en-1-one is prepared using a mixture of 0.1 mole acetophenone and o-nitrobenzaldehyde, which is then dissolved in 25 ml ethanol is stirred, after which an aqueous KOH solution of 15 ml is added. The mixture was refluxed on the water bath for 6 hours. Upon completion of the reaction, which is monitored by thin layer chromatography (TLC) with hexane-chloroform, the mixture is poured into crushed ice and then acidified with dilute HCl. The chalcone precipitates as a solid which is filtered and crystallized from ethanol, the chemical formula of the first compound being C ₁₅ H ₁₁ NO ₃ .

The second compound 1-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)ethanone is prepared by refluxing 0.01 mole of the first compound in 10 ml acetic acid and 0.01 mole hydrazine hydrate in 25 ml of absolute ethanol for 5 hours on the water bath, concentrating the solution by distillation under reduced pressure after the reaction is complete. After cooling, a solid is obtained which is dried and purified by recrystallization from methanol, the chemical formula of the second compound being C ₁₇ H ₁₅ N ₃ O ₃ .

The third compound N-(4-bromobenzylidene)-5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H-1,3,4-thiadiazine -2-amine is prepared by refluxing the mixture of 0.1 mole of the second compound, 0.1 mole of p-bromobenzaldehyde and 0.1 mole of thiosemicarcarbozide in dimethyl carbonate in the presence of the catalyst NH ₄ OAc in a water bath for 5 hours, resulting in the formation of a thiazole vessel -Base leads. The reaction is monitored by thin layer chromatography (TLC) with methanol-chloroform. After the reaction is complete, the reaction mixture is poured into volatile ice, resulting in the precipitation of a solid, which is then filtered and crystallized from ethanol, where the chemical formula of the third compound is C ₂₅ H ₁₉ BrN ₆ O ₂ S .

To prepare the final compound, use 0.01 mole of the third compound, 0.01 mole thioglycolic acid with anhydrous ZnCl ₂ in dimethylformamide (DMF). The mixture is then refluxed for 6 hours and then poured into crushed ice and stirred vigorously. The mixture solidifies within fifteen minutes, then is filtered off and washed with cold water. Recrystallization from ethanol gave an analytically pure sample, the chemical formula of the final compound being C ₂₇ H ₂₁ BrN ₆ O ₃ S ₂ .

The figures and the preceding description give examples of embodiments. Those skilled in the art will understand that one or more of the elements described may well be combined into a single functional element. Alternatively, certain elements can be broken down into multiple functional elements. Elements from one embodiment may be added to another embodiment. For example, the order of the processes described herein may be changed and is not limited to the manner described herein. Additionally, the actions of a flowchart need not be performed in the order shown; Also, not all actions have to be carried out. Also, the actions that are not dependent on other actions can be performed in parallel with the other actions. The scope of the embodiments is in no way limited by these specific examples. Numerous variations are possible, regardless of whether they are explicitly mentioned in the description or not, e.g. B. Differences in structure, dimensions and use of materials. The scope of the embodiments is at least as broad as indicated in the following claims.

Advantages, other benefits, and solutions to problems have been described above with respect to particular embodiments. However, the benefits, advantages, problem solutions, and components that can cause an advantage, benefit, or solution to occur or become more pronounced are not to be construed as a critical, required, or essential feature or component of any or all claims.

Reference List

100

System for Formulating 2-(4-Bromophenyl)-3-(5-(5-(2-Nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H-1,3 ,4-thiadiazine-2-yl)thiazolidin-4-one

102

First compound formulation unit

104

Second mix formulation unit

106

Third mix formulation unit

108

Last mix formulation unit

Claims (6)

System for Formulating 2-(4-Bromophenyl)-3-(5-(5-(2-Nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H-1,3 ,4-thiadiazin-2-yl)thiazolidin-4-one, the system comprising: a first compound formulating unit for preparing the first compound (E)-3-(2-nitrophenyl)-1-phenylprop-2-en-1- on, wherein 0.1 mol of each of acetophenone and o-nitrobenzaldehyde are stirred in 25 ml of ethanol, after which an aqueous KOH solution of 15 ml is added into the stirred mixture, after which the mixture is refluxed in a water bath for 6 hours; a second compound formulating unit for preparing the second compound 1-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)ethanone using a mixture of 0.01 moles of chalcone derivatives in acetic acid of 10 ml and 0.01 M hydrazine hydrate in absolute ethanol of 25 ml is refluxed for 5 hours in a water bath; a third compound formulating unit for preparing the third compound N-(4-bromobenzylidene)-5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H-1, 3,4-thiadiazine-2-amine, using a mixture of 0.1 mole of 1-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)ethanone, 0.1 mole p -bromobenzaldehyde and 0.1 mole of thiosemicarbozide in dimethyl carbonate in the presence of the catalyst NH4OAc is refluxed on the water bath for 5 hours, resulting in the formation of the thiazole Schiff's base; and a final compound formulation unit for preparing the final compound 2-(4-bromophenyl)-3-(5-(5-(2-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-2H- 1,3,4-thiadiazine-2-yl)thiazolidin-4-one using a mixture of 0.01 mole of N-(4-bromobenzylidene)-5-(5-(2-nitrophenyl)-3-phenyl-4,5 -dihydro-1H-pyrazol-1-yl)-2H-1,3,4-thiadiazine-2-amine and 0.01 mole of thioglycolic acid containing a trace of anhydrous ZnCl ₂ in dimethylformamide (DMF) at reflux for 6 hours will. system after claim 1 , wherein the reaction to produce the first compound is monitored by thin layer chromatography (TLC) with hexane-chloroform and the reaction mixture is poured into the crushed ice, which is then acidified with dilute HCl and a chalcone precipitate is obtained, which is then filtered and crystallized with ethanol will. system after claim 1 , wherein the first compound (E)-3-(2-nitrophenyl)-1-phenylprop-2-en-1-one has a melting point of 149-150°C and a molecular weight of 253.25, the yield of the compound being 84% amounts to. system after claim 1 , after completion of the reaction of the second compound, the mixture is concentrated by distillation under reduced pressure and, after cooling, a solid is obtained, which is then dried and purified by recrystallization from methanol, the yield being 81%, mp 153-154 °C and the molecular weight is 309.32. system after claim 1 , wherein the reaction to produce the third compound is monitored by thin layer chromatography (TLC) with hexane-chloroform and the reaction mixture is poured into the crushed ice, after which the compound precipitates as a solid, which is then filtered and crystallized from ethanol, with the yield of the third compound is 79%, the melting point is 131-132°C and the molecular weight is 547.43. system after claim 1 , taking the mixture, which has been refluxed for 6 hours to produce the final compound, then poured into crushed ice and then stirred vigorously, after which it solidifies within 15 minutes, then filtered off and washed with cold water, after which the pure Sample is obtained by recrystallization from ethanol, the yield being 77%, the melting point being 135-136°C and the molecular weight being 621.53.

Images